The 2025/26 season for respiratory diseases is starting in Europe, marked by increased detections of respiratory syncytial virus (RSV) in several countries and rising rates of influenza-like illness infections in primary care settings.
Respiratory syncytial virus (RSV) is a prevalent and pervasive highly transmissible virus within the family Pneumoviridae, leading to respiratory illness of varying severity in humans. Most individuals experience their initial infection during early childhood, with near universal exposure by age two.
This Threat Assessment Brief aims to assess the risk of autochthonous transmission of monkeypox virus (MPXV) clade Ib in EU/EEA countries in the context of male-to-male sexual transmission. It is intended for public health authorities in EU/EEA countries and is based on currently available evidence.
A prolonged cross-border outbreak of Salmonella Strathcona ST2559 is ongoing in the European Union/European Economic Area (EU/EEA). From 2023 to 30 September 2025, 437 confirmed cases of S. Strathcona ST2559 were identified in 17 EU/EEA countries (205 additional cases since the first rapid outbreak assessment published on 12 November 2024).
ECDC cooperates with countries under the EU enlargement policy to improve their infectious disease prevention and control systems and public health workforce to prepare them for their future participation in ECDC’s work.
The current report presents findings from a clinical audit conducted on the PrEP Standards of Care module developed by ECDC in collaboration with EACS, which also serves as a model for future audits on other care standards.
This report presents the findings and recommendations of an assessment conducted in Iceland. This involved a desk review of relevant documents, followed by a five-day country visit that took place between 2 June and 6 June 2025.
ECDC has the responsibility, in coordination with relevant Union agencies and bodies, to conduct Public Health Emergency Preparedness Assessments of all EU/EEA countries every three years regarding the state of implementation of their national prevention, preparedness and response planning.
The objective of this review was to investigate the efficacy, effectiveness, immunogenicity and safety of HPV vaccination in non-HIV immunocompromised individuals of any age.
